Bicycle Therapeutics Ltd
$ 5.06
1.61%
14 Apr - close price
- Market Cap 347,141,000 USD
- Current Price $ 5.06
- High / Low $ 5.35 / 4.98
- Stock P/E N/A
- Book Value 8.79
- EPS -3.16
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.31 %
- 52 Week High 9.55
- 52 Week Low 4.24
About
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
Analyst Target Price
$12.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-10-29 | 2025-08-08 | 2025-04-30 | 2025-02-18 | 2024-10-31 | 2024-08-06 | 2024-05-02 | 2024-02-20 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.29 | -0.85 | -1.14 | -0.88 | -0.8144 | -0.74 | -0.77 | -0.62 | -1.16 | -1.26 | -1.41 | -1.3 |
| Estimated EPS | -0.9372 | -0.9708 | -0.94 | -0.8088 | -0.8536 | -0.78 | -1.1 | -1.24 | -1.23 | -1.17 | -1.29 | -1.07 |
| Surprise | 0.6472 | 0.1208 | -0.2 | -0.0712 | 0.0392 | 0.04 | 0.33 | 0.62 | 0.07 | -0.09 | -0.12 | -0.23 |
| Surprise Percentage | 69.0568% | 12.4433% | -21.2766% | -8.8032% | 4.5923% | 5.1282% | 30% | 50% | 5.6911% | -7.6923% | -9.3023% | -21.4953% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.52 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BCYC
2026-04-08 14:40:40
Morgan Stanley has lowered its price target for Bicycle Therapeutics (BCYC) from $13.00 to $12.00, while maintaining an Equal-Weight rating. This adjustment follows similar price target reductions by other analysts in March 2026. Despite these reductions, the average one-year price target from 11 analysts suggests a significant upside of 153.01% from the current price, with an average brokerage recommendation of "Outperform."
2026-04-07 23:39:05
RBC Capital has adjusted its price target for Bicycle Therapeutics plc (BCYC) downward from $11 to $7. This revision indicates a more cautious outlook from the firm regarding the company's future stock performance.
2026-04-07 00:11:02
Bicycle Therapeutics CEO Kevin Lee sold 5,967 shares on April 2nd and an additional 1,716 shares on April 6th to cover tax withholding on vested equity, reducing his total holdings by 0.96%. The company's stock traded down 3.2% to $4.89 with below-average volume. Despite beating EPS and revenue estimates, Bicycle Therapeutics remains unprofitable, and analysts have a mixed "Hold" rating with an average target price of $14.50.
2026-04-06 22:11:02
Bicycle Therapeutics PLC (BCYC) Chief Financial Officer Travis Alvin Thompson reported the sale of 901 ordinary shares across two transactions on April 2nd and April 6th, 2026. These sales, totaling $4,438, were mandated "sell to cover" transactions to satisfy statutory tax withholding obligations related to the vesting of RSUs, not discretionary sales. After these sales, Thompson directly holds 65,364 ordinary shares of the company.
2026-04-06 22:11:02
Michael Charles Ferguson, an officer at Bicycle Therapeutics (BCYC), sold 1,772 Ordinary Shares in two transactions on April 2 and April 6, 2026. These sales, totaling approximately $8,736, were mandatory "sell to cover" arrangements to satisfy statutory tax withholding obligations arising from the vesting of his Restricted Stock Units (RSUs), and not discretionary market sales. Following these transactions, Ferguson directly holds 96,136 Ordinary Shares in the company.
2026-04-06 22:11:02
Bicycle Therapeutics COO Jennifer Scott Perry sold 1,408 ordinary shares in early April 2026, totaling approximately $6,962. A significant portion of these shares was sold non-discretionarily to cover statutory tax withholding obligations related to restricted stock unit vesting, with one transaction occurring under a pre-arranged Rule 10b5-1 trading plan. Following these sales, Perry still directly holds 92,464 ordinary shares of the company.
